SEP 226330Alternative Names: SEP-0226330; SEP-226330
Latest Information Update: 07 Jul 2011
At a glance
- Originator Sepracor
- Developer Sepracor; Sunovion Pharmaceuticals
- Class Antiparkinsonians
- Mechanism of Action Adrenergic receptor antagonists; Dopamine uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Parkinson's disease; Restless legs syndrome